[228 Pages Report] The global Connected Drug Delivery Devices Market size was estimated at US$ 330 Million in 2021, and is expected to reach US$ 1.6 Billion by 2028, expanding at a stellar CAGR of 23.6%.
| Attribute | Details |
|---|---|
| Connected Drug Delivery Devices Market Size (2022) | US$ 448 Million |
| Sales Forecast (2028) | US$ 1.6 Billion |
| Projected Market Growth Forecast (2022 to 2028) | 23.6% CAGR |
| Regional Market With Highest Share | North America - 51.5% |
Sales of connected drug delivery devices contribute 3.7% share to the global novel drug delivery system market. Drug delivery in nanotechnology has been extensively researched on, and this is expected to spawn new innovative drug delivery methods going ahead.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 25.73% |
| H1, 2022 Projected | 23.59% |
| H1, 2022 Outlook | 22.79% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 80 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 294 ↓ |
With the influence of various macroeconomic, industrial and regulatory variables, the comparative analysis of market growth rate of global connected drug delivery devices market has been studied by Future Market Insights.
As per the study, the global market will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 80 BPS, and, a decline in BPS growth is expected in H1-2022 over H1- 2021 duration with 294 Basis Point Share (BPS).
Key barriers to the broader adoption of connected devices include data privacy laws that may prevent data sharing with HCPs in some countries, as well as the need to demonstrate that the tools are consistently used and generate a high-quality and reproducible database. These factors impose a negative impact as observed in the BPS value change.
However, there are some positive factors that will help push the market growth in the upcoming years which includes growing development of connected drug delivery systems with features like adherence trackers, patient education tools, dose reminders, patient diaries to gather patient-reported outcomes, and monitoring systems with interfaces between patients and healthcare professionals (HCPs).
This will enable patient monitoring and counselling in a home setting, thereby providing lucrative growth opportunities for the market players.
The healthcare industry has seen major changes over the past years, and most of these were driven by increased technological proliferation in the industry. Drug delivery has become one of the most researched areas in the healthcare industry, and since patient engagement has become essential in the medical sector, demand for connected drug delivery devices has also risen significantly.
Injectable drug delivery devices are expected to be most popular over the next few years as they have multiple functionalities and can be used for drug tracking, drug delivery, as well as drug identification. Rising preference for these among the population is expected to boost sales of injectable drug delivery devices over the forecast period.
Rising penetration of IoT (Internet of Things) in the medical industry, advances in drug delivery nanotechnology, innovative product launches, increasing awareness about connected drug therapy, and rising trend of home care are some of the major factors that are positively influencing the sales of connected drug delivery devices across the globe.
Demand for connected drug delivery devices increased at a phenomenal CAGR of 26.3% from 2015 to 2021, and is slated to continue surging at 23.6% CAGR from 2022 to 2028,
This research details the global connected drug delivery devices industry across North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The North America connected drug delivery devices market, which is set to hold a significant market share of 51.5% in 2022, is expected to maintain this dominance over the forecast period as well. Increasing healthcare expenditure and rising awareness are majorly propelling the sales of connected drug delivery devices in the region.
The market for connected drug delivery devices in Europe holds the second-highest market share of over 28%. Demand for connected drug delivery products in Europe is expected to rise at the fastest CAGR among all regions. Rapid growth can be attributed to increasing prevalence of chronic diseases in the region.
Market growth of connected drug delivery devices in East Asia, South Asia, and the Pacific is expected to see limited due to major factors influencing the sales and adoption of connected drug delivery devices. Majorly, high cost of connected drug delivery devices is restraining the market potential in these regions.
Connected drug delivery system manufacturers can target these regions to gain from the untapped market potential with competitive pricing and affordable products.
The connected drug delivery devices market in the MEA region, which merely contributes 1.9% to the global market share, is expected to rise at a sluggish CAGR. This is majorly due to high costs and little to no awareness about connected drug delivery devices.
However, as the region develops, it would offer some good opportunities for manufacturers and distributors of connected drug delivery devices to boost their sales.
Principal Consultant
The healthcare industry in the U.S. has been experiencing great growth over the past few years, and is expected to continue to do so over the forecast period as well. The nation has seen substantial increase in the adoption of connected drug delivery equipment.
Factors such as high per capita healthcare spending, rising adoption of new medical technologies, and increasing awareness about the adverse effects of non-compliance with drug therapy are majorly driving the sales of connected drug delivery products in the U.S.
The Japanese connected drug delivery devices market in 2022 is slated to hold 5.1% share of the global market. The nation is always regarded as one of the most technologically advanced in the world, and it only befits that Japan is leading the adoption of healthcare and medical technologies than most nations.
Japan has very high technological proliferation in the healthcare sector, and this makes it a very lucrative market for connected drug delivery device suppliers. Demand for connected drug delivery equipment is also expected to be boosted by the rising geriatric population in Japan, which is also fuelling demand for home care solutions in the nation.
Sales of connected drug delivery systems are expected to see a rise over the forecast period as the popularity and effectiveness of these devices rise.
Connected drug delivery devices work majorly on two technologies - Bluetooth and near field communication (NFC). Bluetooth technology connected drug delivery devices contribute more than 3/5 of the global revenue of the industry. This segment is expected to further grow as advancements in Bluetooth technology pace over the coming years. Low cost of implementation and easy availability make Bluetooth the first choice for many connected drug delivery device manufacturers.
However, NFC technology connected drug delivery devices are expected to rise at the fastest CAGR as these devices are becoming popular for drug identification and tracking purposes, along with having more flexibility and versatility than Bluetooth-operated devices.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The COVID-19 pandemic of 2020 took the world by storm and exposed the healthcare system. This fueled the already increasing trend of revolutionizing the healthcare infrastructure to better accommodate technological proliferation.
While most markets toppled across the globe in 2020, the connected drug delivery devices market showed good growth even in the face of tough times where most of the world was in lockdown.
Demand for connected drug delivery devices was driven by sudden surge in demand for drug delivery solutions for home care use, since people were prohibited to go out under lockdown restrictions. This led to an increase in the adoption of connected drug delivery devices technology, which has been gaining momentum over the past few years.
Sales of connected drug delivery device producers are expected to continue to grow in the post-pandemic era as awareness about their uses increases on a global scale.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Connected Drug Delivery Devices Market by Product Type:
Connected Drug Delivery Devices Market by End User:
Connected Drug Delivery Devices Market by Application:
Connected Drug Delivery Devices Market by Technology:
Connected Drug Delivery Devices Market by Region:
The connected drug delivery devices market is projected to grow at a remarkable CAGR of 23.6%, reaching a market value of US$ 1.6 billion by 2028.
The region with the maximum uptake of connected drug delivery devices is North America, primarily centered in the United States.
As the popularity of these devices increases, connected drug delivery systems are expected to experience a rise in sales in Japan through 2028.
A significant barrier confronted by manufacturers is the imperative to seamlessly integrate with established healthcare systems.
Factors driving the market growth include the rising prevalence of chronic diseases, demand for personalized healthcare, and improved medication adherence.
The competitive landscape features a mix of established players and emerging companies. Some prominent players include Bayer AG, Propeller Health, West Pharmaceutical Services Inc., and 3M Company, among others.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Market Inclusion and Exclusion
3. Connected Drug Delivery Devices Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Drivers
3.3.1. Supply Side Drivers
3.3.2. Demand Side Drivers
3.4. Restraints
3.5. Trends
4. Global Economic Outlook
4.1. Global Gross Domestic Product by Region & Country
4.2. Global Healthcare Market Indicator
5. North America Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
5.1. Introduction
5.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2028
5.2.1. U.S.
5.2.2. Canada
5.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
5.3.1. Inhalation Devices
5.3.2. Injectable Devices
5.3.2.1. Handheld Injectable Devices
5.3.2.2. Wearable Injectable Devices
5.4. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
5.4.1. Bluetooth
5.4.2. Near Field Communication
5.5. Market Size (US$ Mn) Forecast By Application, 2013-2028
5.5.1. Anaphylaxis
5.5.2. Cardiovascular
5.5.3. Diabetes
5.5.4. Hormone Replacement
5.5.5. Others
5.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
5.6.1. Hospitals
5.6.2. Clinics
5.6.3. Homecare
5.7. Market Attractiveness Analysis
5.7.1. By Product Type
5.7.2. Technology
5.7.3. By Application
5.7.4. By End User
5.7.5. By Country
5.8. Drivers and Restraints: Impact Analysis
5.9. Key Market Participants – Intensity Mapping
6. Latin America Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2028
6.2.1. Brazil
6.2.2. Mexico
6.2.3. Argentina
6.2.4. Rest of Latin America
6.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
6.3.1. Inhalation Devices
6.3.2. Injectable Devices
6.3.2.1. Handheld Injectable Devices
6.3.2.2. Wearable Injectable Devices
6.4. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
6.4.1. Bluetooth
6.4.2. Near Field Communication
6.5. Market Size (US$ Mn) Forecast By Application, 2013-2028
6.5.1. Anaphylaxis
6.5.2. Cardiovascular
6.5.3. Diabetes
6.5.4. Hormone Replacement
6.5.5. Others
6.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
6.6.1. Hospitals
6.6.2. Clinics
6.6.3. Homecare
6.7. Market Attractiveness Analysis
6.7.1. By Product Type
6.7.2. Technology
6.7.3. By Application
6.7.4. By End User
6.7.5. By Country
6.8. Drivers and Restraints: Impact Analysis
6.9. Key Market Participants – Intensity Mapping
7. Western Europe Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
7.1. Introduction
7.2. Market Size (US$ Mn) Forecast By Country, 2013-2028
7.2.1. Germany
7.2.2. U.K
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Rest of Western Europe
7.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
7.3.1. Inhalation Devices
7.3.2. Injectable Devices
7.3.2.1. Handheld Injectable Devices
7.3.2.2. Wearable Injectable Devices
7.4. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
7.4.1. Bluetooth
7.4.2. Near Field Communication
7.5. Market Size (US$ Mn) Forecast By Application, 2013-2028
7.5.1. Anaphylaxis
7.5.2. Cardiovascular
7.5.3. Diabetes
7.5.4. Hormone Replacement
7.5.5. Others
7.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
7.6.1. Hospitals
7.6.2. Clinics
7.6.3. Homecare
7.7. Market Attractiveness Analysis
7.7.1. By Product Type
7.7.2. Technology
7.7.3. By Application
7.7.4. By End User
7.7.5. By Country
7.8. Drivers and Restraints: Impact Analysis
7.9. Key Market Participants – Intensity Mapping
8. Eastern Europe Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
8.1. Introduction
8.2. Market Size (US$ Mn) Forecast By Country, 2013-2028
8.2.1. Russia
8.2.2. Poland
8.2.3. Rest of Eastern Europe
8.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
8.3.1. Inhalation Devices
8.3.2. Injectable Devices
8.3.2.1. Handheld Injectable Devices
8.3.2.2. Wearable Injectable Devices
8.4. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
8.4.1. Bluetooth
8.4.2. Near Field Communication
8.5. Market Size (US$ Mn) Forecast By Application, 2013-2028
8.5.1. Anaphylaxis
8.5.2. Cardiovascular
8.5.3. Diabetes
8.5.4. Hormone Replacement
8.5.5. Others
8.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
8.6.1. Hospitals
8.6.2. Clinics
8.6.3. Homecare
8.7. Market Attractiveness Analysis
8.7.1. By Product Type
8.7.2. Technology
8.7.3. By Application
8.7.4. By End User
8.7.5. By Country
8.8. Drivers and Restraints: Impact Analysis
8.9. Key Market Participants – Intensity Mapping
9. Asia Pacific Excluding China & Japan Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
9.1. Introduction
9.2. Market Size (US$ Mn) Forecast By Country, 2013-2028
9.2.1. India
9.2.2. Australia and New Zealand
9.2.3. ASEAN
9.2.4. Rest of APECJ
9.3. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
9.3.1. Inhalation Devices
9.3.2. Injectable Devices
9.3.2.1. Handheld Injectable Devices
9.3.2.2. Wearable Injectable Devices
9.4. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
9.4.1. Bluetooth
9.4.2. Near Field Communication
9.5. Market Size (US$ Mn) Forecast By Application, 2013-2028
9.5.1. Anaphylaxis
9.5.2. Cardiovascular
9.5.3. Diabetes
9.5.4. Hormone Replacement
9.5.5. Others
9.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
9.6.1. Hospitals
9.6.2. Clinics
9.6.3. Homecare
9.7. Market Attractiveness Analysis
9.7.1. By Product Type
9.7.2. Technology
9.7.3. By Application
9.7.4. By End User
9.7.5. By Country
9.8. Drivers and Restraints: Impact Analysis
9.9. Key Market Participants – Intensity Mapping
10. China Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
10.2.1. Inhalation Devices
10.2.2. Injectable Devices
10.2.2.1. Handheld Injectable Devices
10.2.2.2. Wearable Injectable Devices
10.3. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
10.3.1. Bluetooth
10.3.2. Near Field Communication
10.4. Market Size (US$ Mn) Forecast By Application, 2013-2028
10.4.1. Anaphylaxis
10.4.2. Cardiovascular
10.4.3. Diabetes
10.4.4. Hormone Replacement
10.4.5. Others
10.5. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Homecare
10.6. Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. Technology
10.6.3. By Application
10.6.4. By End User
10.7. Drivers and Restraints: Impact Analysis
10.8.Key Market Participants – Intensity Mapping
11. Japan Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
11.1.Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
11.2.1. Inhalation Devices
11.2.2. Injectable Devices
11.2.2.1. Handheld Injectable Devices
11.2.2.2. Wearable Injectable Devices
11.3. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
11.3.1. Bluetooth
11.3.2. Near Field Communication
11.4. Market Size (US$ Mn) Forecast By Application, 2013-2028
11.4.1. Anaphylaxis
11.4.2. Cardiovascular
11.4.3. Diabetes
11.4.4. Hormone Replacement
11.4.5. Others
11.5. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Homecare
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. Technology
11.6.3. By Application
11.6.4. By End User
11.7. Drivers and Restraints: Impact Analysis
11.8. Key Market Participants – Intensity Mapping
12. Middle East and Africa Connected Drug Delivery Devices Market Analysis and Forecast 2013–2028
12.1. Introduction
12.2. Regional Market Trends
12.3. Market Size (US$ Mn) Forecast By Country, 2013-2028
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East and Africa
12.4. Historical Market Size (US$ Mn) Trend Analysis By Product Type, 2013-2028
12.4.1. Inhalation Devices
12.4.2. Injectable Devices
12.4.2.1. Handheld Injectable Devices
12.4.2.2. Wearable Injectable Devices
12.5. Historical Market Size (US$ Mn) Trend Analysis By Technology, 2013-2021
12.5.1. Bluetooth
12.5.2. Near Field Communication
12.6. Market Size (US$ Mn) Forecast By Application, 2013-2028
12.6.1. Anaphylaxis
12.6.2. Cardiovascular
12.6.3. Diabetes
12.6.4. Hormone Replacement
12.6.5. Others
12.7. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2028
12.7.1. Hospitals
12.7.2. Clinics
12.7.3. Homecare
12.8. Market Attractiveness Analysis
12.8.1. By Product Type
12.8.2. Technology
12.8.3. By Application
12.8.4. By End User
12.8.5. By Country
12.9. Drivers and Restraints: Impact Analysis
12.10. Key Market Participants – Intensity Mapping
13. Forecast Factors: Relevance and Impact
14. Forecast Assumptions
15. Market Structure Analysis
15.1.Market Structure by Tier
15.2.Market Share Analysis (2016) for Top Players, By Region
16. Competition Analysis
16.1.Competition Dashboard
16.2.Competitors Deep Dive
16.2.1. Bayer AG
16.2.1.1. Overview
16.2.1.2. Product and Application Portfolio
16.2.1.3. Production Footprint
16.2.1.4. Sales Footprint
16.2.1.5. Channel Footprint
16.2.1.6. Strategy
16.2.1.6.1. Marketing Strategy
16.2.1.6.2. Product Strategy
16.2.1.6.3. Channel Strategy
16.2.2. Propeller Health
16.2.2.1. Overview
16.2.2.2. Product and Application Portfolio
16.2.2.3. Production Footprint
16.2.2.4. Sales Footprint
16.2.2.5. Channel Footprint
16.2.2.6. Strategy
16.2.2.6.1. Marketing Strategy
16.2.2.6.2. Product Strategy
16.2.2.6.3. Channel Strategy
16.2.3. West Pharmaceutical Services, Inc.
16.2.3.1. Overview
16.2.3.2. Product and Application Portfolio
16.2.3.3. Production Footprint
16.2.3.4. Sales Footprint
16.2.3.5. Channel Footprint
16.2.3.6. Strategy
16.2.3.6.1. Marketing Strategy
16.2.3.6.2. Product Strategy
16.2.3.6.3. Channel Strategy
16.2.4. 3M Company
16.2.4.1. Overview
16.2.4.2. Product and Application Portfolio
16.2.4.3. Production Footprint
16.2.4.4. Sales Footprint
16.2.4.5. Channel Footprint
16.2.4.6. Strategy
16.2.4.6.1. Marketing Strategy
16.2.4.6.2. Product Strategy
16.2.4.6.3. Channel Strategy
16.2.5. OPKO Health
16.2.5.1. Overview
16.2.5.2. Product and Application Portfolio
16.2.5.3. Production Footprint
16.2.5.4. Sales Footprint
16.2.5.5. Channel Footprint
16.2.5.6. Strategy
16.2.5.6.1. Marketing Strategy
16.2.5.6.2. Product Strategy
16.2.5.6.3. Channel Strategy
16.2.6. Sagentia (Science Group)
16.2.6.1. Overview
16.2.6.2. Product and Application Portfolio
16.2.6.3. Production Footprint
16.2.6.4. Sales Footprint
16.2.6.5. Channel Footprint
16.2.6.6. Strategy
16.2.6.6.1. Marketing Strategy
16.2.6.6.2. Product Strategy
16.2.6.6.3. Channel Strategy
16.2.7. Cohero Health
16.2.7.1. Overview
16.2.7.2. Product and Application Portfolio
16.2.7.3. Production Footprint
16.2.7.4. Sales Footprint
16.2.7.5. Channel Footprint
16.2.7.6. Strategy
16.2.7.6.1. Marketing Strategy
16.2.7.6.2. Product Strategy
16.2.7.6.3. Channel Strategy
16.2.8. Care TRx
16.2.8.1. Overview
16.2.8.2. Product and Application Portfolio
16.2.8.3. Production Footprint
16.2.8.4. Sales Footprint
16.2.8.5. Channel Footprint
16.2.8.6. Strategy
16.2.8.6.1. Marketing Strategy
16.2.8.6.2. Product Strategy
16.2.8.6.3. Channel Strategy
16.2.9. CeQur SA
16.2.9.1. Overview
16.2.9.2. Product and Application Portfolio
16.2.9.3. Production Footprint
16.2.9.4. Sales Footprint
16.2.9.5. Channel Footprint
16.2.9.6. Strategy
16.2.9.6.1. Marketing Strategy
16.2.9.6.2. Product Strategy
16.2.9.6.3. Channel Strategy
16.2.10. Biocorp Production SA
16.2.10.1. Overview
16.2.10.2. Product and Application Portfolio
16.2.10.3. Production Footprint
16.2.10.4. Sales Footprint
16.2.10.5. Channel Footprint
16.2.10.6. Strategy
16.2.10.6.1. Marketing Strategy
16.2.10.6.2. Product Strategy
16.2.10.6.3. Channel Strategy
17. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028, By Region
17.1. Introduction / Key Findings
17.2. Market Size (US$ Mn) Forecast By Region
17.2.1. North America
17.2.2. Western Europe
17.2.3. Eastern Europe
17.2.4. Latin America
17.2.5. Asia Pacific Excluding Japan And China
17.2.6. China
17.2.7. Japan
17.2.8. Middle East and Africa
17.3. Market Attractiveness Analysis By Region
18. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028, By Product Type
18.1. Introduction/Key Finding
18.2. Market Size (US$ Mn) Forecast By Product Type, 2013-2028
18.2.1. Inhalation Devices
18.2.2. Injectable Devices
18.2.2.1. Handheld Injectable Devices
18.2.2.2. Wearable Injectable Devices
18.3. Market Attractiveness Analysis By Product Type
19. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028, By Technology
19.1. Introduction/Key Finding
19.2. Market Size (US$ Mn) Forecast By Technology, 2013-2028
19.2.1. Bluetooth
19.2.2. Near Field Communication
19.3. Market Attractiveness Analysis By Technology
20. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028, By Application
20.1. Introduction/Key Finding
20.2. Market Size (US$ Mn) Forecast By Application, 2013-2028
20.2.1. Anaphylaxis
20.2.2. Cardiovascular
20.2.3. Diabetes
20.2.4. Hormone Replacement
20.2.5. Others
20.3. Market Attractiveness Analysis By Application
21. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028, By End User
21.1. Introduction/Key Finding
21.2.Market Size (US$ Mn) Forecast By End User, 2013-2028
21.2.1. Hospitals
21.2.2. Clinics
21.2.3. Homecare
21.3.Market Attractiveness Analysis By End User
22. Global Connected Drug Delivery Devices Market Analysis Forecast 2013–2028
22.1.Market Value Share Analysis By All Segment
22.2.Y-o-Y Growth Analysis By All Segment
22.3.Absolute $ Opportunity
23. Assumptions and Acronyms Used
24. Research Methodology
Healthcare
October 2022
REP-GB-4400
222 pages
Explore Healthcare Insights
View Reports
Connected Drug Delivery Devices Market
